Bronchodilator response and lung function decline: Associations with exhaled nitric oxide with regard to sex and smoking status

Nerpin, Elisabet; Ferreira, Diogenes S.; Weyler, Joost; Schlunnsen, Vivi; Jõgi, Rain; Semjen, Chantal Raherison; Gislasson, T.; Demoly, Pascal; Heinrich, Joachim; Nowak, Dennis; Corsico, Angelo Guido; Accordini, Simone; Marcon, Alessandro; Squillacioti, Giulia; Olivieri, Mario; Nielsen, Rune; Johannessen, Ane; Real, Francisco Gómez; Garcia‐Aymerich, Judith; Urrutia, Isabel; Pereira‐Vega, Antonio; Blanco, José Antonio Gullón; Olin, Anna Carin; Forsberg, Bertil; Emilsson, Össur Ingi; Pin, Isabelle; Jarvis, Déborah; Janson, Christer; Malinovschi, Andreï

doi:10.1016/j.waojou.2021.100544

Cited by 8 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 6 studies [ 31 , 34 , 46 , 55 , 57 , 60 ] RCTs, 4 studies [ 32 , 33 , 58 , 62 ] were retrospective observational, 3 studies [ 36 , 38 , 40 ] were prospective observational, and 1 study [ 35 ] was focused on pharmacodynamics (PD). Eight [ 41 , 44 , 48 , 49 , 52 , 59 ] studies were post-hoc analyses of RCTs and another one [ 37 ] of an observational study, 6 studies [ 39 , 42 , 45 , 50 , 51 , 54 ] were pooled analyses of RCTs , 2 studies [ 43 , 56 ] were subgroup analyses of RCTs, 1 study [ 61 ] was an extended analysis of a RCT, and 1 study [ 47 ] was a sensitivity analysis of a RCT.…”

Section: Resultsmentioning

confidence: 99%

“…In a recent analysis of data from the third European Community Respiratory Health Survey (ECRHS III) [ 36 ], the bronchodilator (BD) response to SALB 200 μg with regards to FEV 1 /forced vital capacity (FVC) was superior in asthmatic women than in men (4.1, 95%CI 3.6–4.6 vs. 3.0, 95%CI 2.5–3.6; P < 0.01 vs. pre-BD). The BD response with respect to FEV 1 was improved in both men (4.9, 95%CI 4.1–5.8; P < 0.05 vs. pre-BD) and women (5.0, 95%CI 4.2–5.7; P < 0.05 vs. pre-BD).…”

Section: Resultsmentioning

confidence: 99%

“…The BD response with respect to FEV 1 was improved in both men (4.9, 95%CI 4.1–5.8; P < 0.05 vs. pre-BD) and women (5.0, 95%CI 4.2–5.7; P < 0.05 vs. pre-BD). The increase in FEV 1 was positively associated with the fraction exhaled of nitric oxide levels after BD use in women (P < 0.05), whereas men showed no difference [ 36 ].…”

Section: Resultsmentioning

confidence: 99%

“…The overall quality of evidence from the observational cohort and cross-sectional studies, assessed respectively via the NOS score and JBI Checklist tool, is presented in Table 1 . Two cohort studies [ 38 , 40 ] were given a NOS score ≥ 7 and were considered of high quality, whereas four studies [ 33 , 36 , 37 ] were assigned a score of ≤ 6. Quality assessment of cross-sectional studies indicated that one study [ 58 ] was at high risk of bias for the evaluated outcomes, another one [ 62 ] was at medium risk, and the study performed by Siroux et al [ 32 ] was at low risk of bias.…”

Section: Resultsmentioning

confidence: 99%

“…Of the 90 potentially relevant records identified in the initial search, 32 studies were deemed eligible for a qualitative synthesis (Table 1). This systematic review included data obtained from studies performed on patients with asthma [31][32][33][34][35][36][37][38][39], COPD , and populations in which both asthmatic and COPD patients were included [62].…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Sex differences in adult asthma and COPD therapy: a systematic review

et al. 2022

View full text Add to dashboard Cite

Background Although asthma is more prevalent in women and the prevalence of COPD is increasing in women, the current international recommendations for the management and prevention of asthma and COPD provide no sex-related indication for the treatment of these diseases. Therefore, we systematically reviewed the evidence across literature on the sex-related effectiveness of asthma and COPD therapy. Methods This systematic review has been registered in PROSPERO and performed according to PRISMA-P. The PICO framework was applied for the literature search strategy: "patient problem” included adult patients suffering from asthma or COPD, “Intervention” regarded the pharmacological treatments for asthma or COPD, “Comparison” was vs. baseline, active controls, or placebo, “Outcome” was any difference sex-related in the effectiveness of interventions. Results In asthma 44% of the evidence reported that men responded better than women to the therapy, whereas this percentage was 28% in COPD. ICS was generally less effective in women than in men to treat asthma, and consistent evidence suggests that in asthmatic patients ICS/LABA/LAMA combination may be equally effective in both men and women. Due to the inconsistent available evidence, it is not possible to identify specific treatments whose effectiveness is related to sex difference in COPD patients. Conclusions There is a strong need of investigating the sex-related impact of asthma and COPD treatments. Pre-specified analyses in men and women should be planned in future trial protocols, a necessary condition that should be requested also by the regulatory agencies to overcome the anachronistic “one-size-fits-all” approach to therapeutics associated with suboptimal outcomes for patients.

show abstract